Cargando…

Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) is the most aggressive type of breast cancer. A recent study demonstrated the efficacy of anti-PD-L1 (anti-programmed death ligand-1) immunotherapy in patients with TNBC. However, the identification of TNBC patients who may benefit from immunotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshikawa, Katsuhiro, Ishida, Mitsuaki, Yanai, Hirotsugu, Tsuta, Koji, Sekimoto, Mitsugu, Sugie, Tomoharu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8462691/ https://www.ncbi.nlm.nih.gov/pubmed/34559865 http://dx.doi.org/10.1371/journal.pone.0257860

Ejemplares similares

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2021)

Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2021)

Adipophilin expression is an independent marker for poor prognosis of patients with triple-negative breast cancer: An immunohistochemical study
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2020)

Immunohistochemical analyses of the expression profiles of INSM1, ATRX, DAXX and DLL3 in solid papillary carcinomas of the breast
por: Yanai, Hirotsugu, et al.
Publicado: (2022)

Prognostic significance of the expression levels of T-cell immunoglobulin mucin-3 and its ligand galectin-9 for relapse-free survival in triple-negative breast cancer
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2022)

Association between fatty acid synthase and adipophilin expression in triple-negative breast cancer
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2022)

Prognostic significance of adipophilin expression in biopsy specimens of patients with triple-negative breast cancer
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2022)

Presence of myxoid stromal change and fibrotic focus in pathological examination are prognostic factors of triple-negative breast cancer: Results from a retrospective single-center study
por: Yanai, Hirotsugu, et al.
Publicado: (2021)

Direct comparison of magnetic resonance imaging and pathological shrinkage patterns of triple-negative breast cancer after neoadjuvant chemotherapy
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2020)

Intramural bronchogenic cysts of the esophagus and gastroesophageal junction: A case report
por: Matsuda, Hayato, et al.
Publicado: (2020)

Quantitative immunohistochemical assay with novel digital immunostaining for comparisons of PD-L1 antibodies
por: Fujisawa, Takuo, et al.
Publicado: (2019)

Immunohistochemical analysis of SOX2 expression in small-cell neuroendocrine carcinoma of the endometrium
por: Ebisu, Yusuke, et al.
Publicado: (2020)

Four immunohistochemical assays to measure the PD-L1 expression in malignant pleural mesothelioma
por: Watanabe, Takuya, et al.
Publicado: (2018)

Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types
por: Scognamiglio, Giosuè, et al.
Publicado: (2016)

Expression of Programmed Death Ligand1 (PD-L1) in Gastric Carcinoma (Histopathological and Immunohistochemical Study)
por: Ali, Safa Mohammed, et al.
Publicado: (2023)

Comparison of PD-L1 immunohistochemical assays and the significance of PD-L1 expression in thymoma
por: Yokoyama, Shintaro, et al.
Publicado: (2020)

Case report: administration of immune checkpoint inhibitor for SMARCB1 (INI1)-negative rhabdoid carcinoma with microsatellite instability (MSI)-high in the right colon
por: Kobayashi, Toshinori, et al.
Publicado: (2023)

A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma
por: Sakane, Tadashi, et al.
Publicado: (2018)

Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer
por: Noske, Aurelia, et al.
Publicado: (2021)

Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies
por: Sun, Woo Young, et al.
Publicado: (2016)

Wagner-Meissner neurilemmoma of the lip occurring in a patient with neurofibromatosis type 1: A case report
por: Miyasaka, Chika, et al.
Publicado: (2020)

Usefulness and problems of cytological examination by endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of mediastinal lymphadenopathy: A retrospective single-centre study
por: Sandoh, Kaori, et al.
Publicado: (2021)

Immunohistochemical expression of programmed death-ligand 1 and CD8 in glioblastomas
por: El Samman, Dina Mohamed, et al.
Publicado: (2021)

Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors
por: Igarashi, Tomoyuki, et al.
Publicado: (2016)

Significance of desmoplastic reactions on tumor deposits in patients with colorectal cancer
por: Kobayashi, Toshinori, et al.
Publicado: (2022)

Immunohistochemical Expression of Programmed Cell Death Ligand 1 (PD-L1) in Human Cutaneous Malignant Melanoma: A Narrative Review with Historical Perspectives
por: Cazzato, Gerardo, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

The interaction between the soluble programmed death ligand-1 (sPD-L1) and PD-1(+) regulator B cells mediates immunosuppression in triple-negative breast cancer
por: Li, Xuejiao, et al.
Publicado: (2022)

Immunohistochemical Study of the PD-1/PD-L1 Pathway in Cutaneous Lupus Erythematosus
por: Király, Zsófia, et al.
Publicado: (2022)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Tumor budding may be a promising prognostic indicator in intrahepatic cholangiocarcinoma: A multicenter retrospective study
por: Kosaka, Hisashi, et al.
Publicado: (2022)

Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
por: Lawson, Nicola L., et al.
Publicado: (2019)

Novel pathological predictive factors for extranodal extension in oral squamous cell carcinoma: a retrospective cohort study based on tumor budding, desmoplastic reaction, tumor-infiltrating lymphocytes, and depth of invasion
por: Noda, Yuri, et al.
Publicado: (2022)

Immunohistochemical assessment of PD-L1 expression using three different monoclonal antibodies in triple negative breast cancer patients
por: Schmidt, Gilda, et al.
Publicado: (2022)

Correction: Mapping the binding sites of antibodies utilized in programmed cell death ligand-1 predictive immunohistochemical assays for use with immuno-oncology therapies
por: Lawson, Nicola L., et al.
Publicado: (2019)

Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
por: Kataoka, Hiroshi, et al.
Publicado: (2021)

Assessment of programmed death-ligand 1 receptor immunohistochemical expression and its association with tumor-infiltrating lymphocytes and p53 status in triple-negative breast cancer
por: Deacu, Mariana, et al.
Publicado: (2021)

Programmed Death Ligand 1 Immunohistochemistry in Triple-Negative Breast Cancer: Evaluation of Inter-Pathologist Concordance and Inter-Assay Variability
por: Ahn, Soomin, et al.
Publicado: (2021)

Programmed Death Ligand 1 (PD-L1) Expression in Primary Angiosarcoma
por: Botti, Gerardo, et al.
Publicado: (2017)

Programmed death ligand 1 (PD-L1) expression in parathyroid tumors
por: Pan, Boju, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gom2gob8olss5djvim2d4hvvq9